使用射波刀的大剂量立体定向体部放疗治疗I期周围型肺癌:单中心回顾性研究
本单中心回顾性研究纳入2010年8月至2019年6月接受射波刀立体定向体部放疗的96例I期周围型非小细胞肺癌患者,评估局部控制、生存及晚期毒性。处方剂量54 Gy/3次91例、60 Gy/3次5例,中位随访27个月,2年局部控制率97%、总生存率90%;T分期与局部控制、无进展生存显著相关,1例(1%)发生3级放射性肺炎。
要点
- 96例I期周围型非小细胞肺癌接受射波刀SBRT,2年局部控制率97%、总生存率90%。
- T1a/T1b与T1c/T2a的2年局部控制率为100%对90%,2年无进展生存率为95%对65%。
- 1例(1%)发生3级放射性肺炎;作者认为需进一步研究改善T1c/T2a疗效。
核心结论
- 作者认为,射波刀大剂量SBRT治疗I期周围型非小细胞肺癌可获得良好治疗结果,晚期毒性可接受。
- 作者指出,需进一步研究以改善T1c/T2a疾病患者的治疗结果。
研究设计与样本
- 单中心回顾性研究,纳入2010年8月至2019年6月接受射波刀SBRT的96例I期周围型非小细胞肺癌患者。
- 评估局部控制、局部无进展生存、无进展生存、总生存及晚期毒性,并通过单因素分析探讨与局部控制、局部无进展生存、无进展生存或总生存相关的潜在危险因素。
主要发现
- 91例患者肿瘤处方剂量为54 Gy分3次,5例为60 Gy分3次,中位随访27个月。
- 2年局部控制率、局部无进展生存率、无进展生存率和总生存率分别为97%、88%、84%和90%。
- T因子与局部控制、局部无进展生存和无进展生存显著相关。
- T1a/T1b与T1c/T2a患者的2年局部控制率分别为100%和90%(p < 0.05),2年无进展生存率分别为95%和65%(p < 0.001)。
- 1例(1%)患者发生3级放射性肺炎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This retrospective study was performed to evaluate the efficacy and toxicity of high-dose stereotactic body radiotherapy (SBRT) using a CyberKnife® for patients with stage I peripheral non-small cell lung cancer (NSCLC). METHODS: Ninety-six patients with stage I peripheral NSCLC who were treated with SBRT using a CyberKnife® from August 2010 to June 2019 were identified and included in this study. Local control (LC), local progression-free survival (LPFS), progression-free survival (PFS), overall survival (OS), and late toxicity were evaluated. Potential risk factors associated with LC, LPFS, PFS, or OS were investigated by univariate analyses. RESULTS: Data of 96 patients were examined. The prescribed dose to the tumor was 54 Gy in 3 fractions in 91 patients and 60 Gy in 3 fractions in 5 patients. The median follow-up duration was 27 months. The 2-year LC, LPFS, PFS, and OS rates were 97%, 88%, 84%, and 90%, respectively. The T factor was significantly correlated with LC, LPFS, and PFS. The 2-year LC rate for patients with T1a/T1b and T1c/T2a disease was 100% and 90%, respectively (p < 0.05), and the 2-year PFS rate for the corresponding patients was 95% and 65%, respectively (p < 0.001). One patient (1%) developed grade 3 radiation pneumonitis. CONCLUSIONS: High-dose SBRT using a CyberKnife® for stage I peripheral NSCLC produced favorable treatment outcomes with acceptable late toxicity. Further studies are needed to improve the treatment outcomes for patients with T1c/T2a disease.
引用
- Ryuno Y, Abe T, Iino M, et al. High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study. Radiat Oncol. 2022. PMID: 35854333. doi:10.1186/s13014-022-02094-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。